Pragmatic randomised trial of a smartphone app (NRT2Quit) to improve effectiveness of nicotine replacement therapy in a quit attempt by improving medication adherence: results of a prematurely terminated study.

Plain-language guide to PMID 31477166 (2019): randomized and double-blind pragmatic clinical trial of Therapeutic nicotine (patch, non-peptide).

Key Facts

PMID: 31477166
Journal: Trials
Year: 2019
Study type: Pragmatic Clinical Trial
Authors: Herbec A et al. (5 authors)
DOI: 10.1186/s13063-019-3645-4

What This Study Did, in Plain Language

What Was Tested

This pragmatic clinical trial looks at Therapeutic nicotine (patch, non-peptide).

ISRCTN ISRCTN33423896, prospectively registered on 22 March 2015.

Who Took Part

PubMed indexes the participants as adults, both men and women.

Participants were automatically randomly assigned within the app to the intervention (full) version of NRT2Quit or to its control (minimal) versions.

The primary outcome was biochemically verified 4-week abstinence assessed at 8-week follow-up using Russell Standard criteria and intention to treat.

How the Study Was Run

In design terms this was a randomized and double-blind study.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.

Bayes factors were calculated for the cessation outcome.

Secondary outcomes were self-reported abstinence, NRT use, app use and satisfaction with the app.

What Was Measured

PubMed files the paper under topics including Medication Adherence, Mobile Applications, Outcome Assessment, Health Care, Patient Satisfaction, Smartphone, Smoking Cessation and Tobacco Use Cessation Devices.

The authors tagged it with the keywords Nicotine replacement therapy and Smartphone application.

What This Means in Plain Language

The paper is a randomized and double-blind study of Therapeutic nicotine (patch, non-peptide).

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (Trials), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Therapeutic nicotine (patch, non-peptide) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.